DUBLIN, Mar 08, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Human Growth Hormone (HGH) - Market Outlook 2022" report to their offering.

Owing to growth stimulating properties of HGH, excessive secretion leads to acromegalic gigantism; while deficiency of GH leads to Growth Hormone Deficiency (GHD), which is a chronic disease affecting both children and adults. GHD in children is characterized by reduced growth performance and a loss of height in comparison to peers. GHD during adulthood manifests symptoms like weight gain, reduced energy levels, disturbed sleep, etc. Standard therapies for treatment of GHD includes administration of recombinant human growth hormone through injections, releasers, sprays, etc.

Growth of the global Human Growth Hormone market is driven by increase in prevalence of pituitary dysfunction, growing geriatric population, high market opportunity due to lower rHGH market penetration across nations, rising healthcare expenditure and affordability. Major factors restraining growth of the market are high treatment cost of rHGH, adverse side-effects of synthetic HGH, illicit use of HGH, poor adherence to therapy by patients and stringent regulatory approvals involved.

In the report, human growth hormone market assessment is done across major markets such as Europe, The US and Japan. The US is the world's largest HGH market accounting for more than one-third of global HGH market value. In-depth analysis of HGH therapy in aforementioned regions is done on the basis of overall HGH market value as well as pediatric HGH market.

Global human growth hormone therapy industry is highly consolidated with three major players - Novo Nordisk, Pfizer and Eli Lilly and Company dominating the market. These industry players as well as other leading players such as Merck KGaA and Roche are profiled herein based on attributes such as business overview, product segments, financial and business strategies. The report also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global HGH therapy market.

Key Topics Covered:

1. Executive Summary

2. Research Methodology

3. Human Growth Hormone
    3.1 Overview
    3.2 The Pathophysiology of Growth Hormone
        3.2.1 Molecular Basis of GH Action
        3.2.2 Metabolic Effects of GH
    3.3 Growth Hormone Deficiency
        3.3.1 Pediatric GHD
        3.3.2 Adult GHD
        3.3.3 Other Diorders
    3.4 Recombinant HGH
        3.4.1 Inclusion Body Technology
        3.4.2 Protein Secretion Technology
        3.4.3 Mouse-Cell Technology

4. Human Growth Hormone Market Analysis
    4.1 Market Sizing
        4.1.1 Market Size by Value (Actual & Forecasted)
        4.1.2 Market Size by Volume (Actual & Forecasted)
        4.1.3 Market Share by Region
    4.2 HGH Market by Segment
        4.2.1 Market Share
        4.2.2 Pediatric GHD market
        4.2.3 Adult GHD market

5. GH Deficiency Therapy
    5.1 Diagnosis
    5.2 Therapy for Various GHDs
    5.3 Treatment Options
        5.3.1 HGH Injections
        5.3.2 HGH Releasers
        5.3.3 Homeopathic HGH
        5.3.4 Others
    5.4 Human Growth Hormone (HGH) Replacement
        5.4.1 Overview
        5.4.2 Benefits of HGH Replacement

6. Global HGH Market Regional/Country Analysis
    6.1 Europe
        6.1.1 Overview
        6.1.2 rhGH Market Sizing (Actual & Forecasted)
        6.1.1 Pediatric rhGH Market Sizing (Actual & Forecasted)
    6.2 The US
        6.2.1 Overview
        6.2.2 rhGH Market Sizing (Actual & Forecasted)
        6.2.1 Pediatric rhGH Market Sizing (Actual & Forecasted)
    6.3 Japan
        6.3.1 Overview
        6.3.2 rhGH Market Sizing (Actual & Forecasted)
        6.3.1 Pediatric rhGH Market Sizing (Actual & Forecasted)

7. Global HGH Market Dynamics
    7.1 Industry Trends & Developments
        7.1.1 Advent of Long-acting rhGH
        7.1.2 Use of HGH as Performance Enhancers
        7.1.3 Products Under Development
    7.2 Growth Drivers
        7.2.1 Prevalence of Pituitary Dysfunction
        7.2.2 Low Market Penetration
        7.2.3 Growing Geriatric Population
        7.2.4 Rising Healthcare Expenditure and Affordability
    7.3 Challenges
        7.3.1 High Treatment Cost
        7.3.2 Adverse Side-effects of rhGH
        7.3.3 Illicit Uses of HGH
        7.3.4 Reimbursement Issues for Patients
        7.3.5 Poor Adherence to Therapy by Patient
        7.3.6 Stringent Regulatory Approvals

8. Competitive Landscape
    8.1 Brand Analysis
    8.2 Drugs by Disorders
    8.3 Market Share by Competitors

9. Company Profiles
    9.1 Merck Serono
    9.2 Novo Nordisk
    9.3 Pfizer
    9.4 Eli Lilly
    9.5 F. Hoffmann-La Roche Ltd.

For more information about this report visit http://www.researchandmarkets.com/research/dlvnlt/global_human

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets